Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 56

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 56
---
 officers. The performance measures involving our financial results could be determined in accordance with generally accepted accounting principles (“GAAP”), or such financial results could consist of non-GAAP financial measures, and any actual results were subject to adjustment by the Compensation Committee for one-time items or unbudgeted or unexpected items when determining whether the target levels for the performance measures had been met. Individual performance objectives could be established on the basis of any factors the Compensation Committee determined relevant, and were subject to adjustment on an individual, divisional, business unit, or Company-wide basis.

Under the 2024 Bonus Plan, the Compensation Committee could, in its sole discretion and at any time, increase, reduce, or eliminate a participant’s actual bonus payment, and/or increase, reduce, or eliminate the amount allocated to the bonus pool for the year. Further, the actual bonus payment for any participant could be below, at, or above a participant’s target bonus opportunity, in the Compensation Committee’s sole discretion. The Compensation Committee could determine the amount of any reduction on the basis of such factors as it deemed relevant, and it was not required to establish any allocation or weighting with respect to the factors it considers. During 2024, the Compensation Committee did not exercise any such individual discretion in determining bonus payouts.

<div align='center'>33</div>

#### Target Bonus Opportunities
For 2024, the target annual cash bonus opportunities for each of our Named Executive Officers under the 2024 Bonus Plan, expressed as a percentage of his annual base salary, were as follows:

| Named Executive Officer        |     |   Annual 
     Base 
   Salary |     | Target Bonus Opportunity         
 (as a percentage of base salary) |     |      Target 
       Bonus 
 Opportunity |     |   Actual 
    Bonus 
   Payout |
| Carsten Brunn, Ph.D.           |     | $642,720 |     | 55%                              |     |    $353,500 |     | $459,545 |
| Blaine Davis                   |     | $462,000 |     | 40%                              |     |    $184,800 |     | $240,240 |
| Metin Kurtoglu, M.D., Ph.D.(1) |     | $440,000 |     | 40%                              |     |    $176,000 |     | $228,800 |
| Christopher Jewell, Ph.D.(2)   |     | $420,000 |     | 40%                              |